Vertex Pharmaceuticals Incorporated (VRTX) Leerink's Global Healthcare Conference 2025 (Transcript)Seeking Alpha • 03/10/25
Vertex Announces UK MHRA Approval of ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic FibrosisBusiness Wire • 03/07/25
Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy RatingSeeking Alpha • 03/06/25
Vertex Pharmaceuticals Incorporated (VRTX) TD Cowen 45th Annual Health Care Conference (Transcript)Seeking Alpha • 03/03/25
Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare MutationsBusiness Wire • 02/28/25
High-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment modelsCNBC • 02/18/25
Levi & Korsinsky Announces an Investigation on Behalf of Vertex Pharmaceuticals Incorporated (VRTX) Shareholders Who May Have Been Affected by FraudAccesswire • 02/14/25
Vertex Pharmaceuticals Gets a Huge FDA Approval Which Could Send the Stock SkyrocketingThe Motley Fool • 02/14/25
Vertex Pharmaceuticals Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - VRTXAccesswire • 02/13/25
Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain.Investors Business Daily • 02/11/25
VRTX ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Vertex Pharmaceuticals Incorporated investmentAccesswire • 02/11/25